Replies to post #406 on Corcept Therapeutics, Inc. (CORT)

[Thurly]

I asked Corcept about the two patients that were partial responders (at least 30% reduction of target tumors' "longest diameter" total) and got the following reply:

. . . of the two responders, both were breast cancer patients (1 was triple negative breast cancer, 1 was classified as metastatic breast cancer).

[Bio_Tech_Boss]

Good response rate for the 2 of 7 GR+ patients.